News Releases

Date Title and Summary
Toggle Summary electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J. , Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be presenting at the Canaccord Genuity 42nd Annual Growth Conference.
Toggle Summary electroCore Announces Record Second Quarter 2022 Financial Results
Record second quarter 2022 net sales of $2.2 million , increased 70% over second quarter 2021 and 14% sequentially Company to host a conference call and webcast today, August 4, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore to Announce Second Quarter 2022 Financial Results on August 4
ROCKAWAY, N.J. , July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the second quarter ended June 30, 2022 , after the close of the market on Thursday, August 4, 2022 .
Toggle Summary electroCore Provides Select Second Quarter 2022 Financial Guidance
Record   revenue will be at least $2.1 million ; approximately 65% growth over second quarter 2021 June 30, 2022 , cash and cash equivalents balance of approximately $26.6 million   ROCKAWAY, N.J. , July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a
Toggle Summary electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
ROCKAWAY, N.J. , July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiated study to assess the efficacy of gammaCore Sapphire non-invasive vagus nerve stimulation (nVNS)
Toggle Summary electroCore Announces Listing Transfer to the Nasdaq Capital Market
ROCKAWAY, N.J. , June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq
Toggle Summary electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
ROCKAWAY, N.J. , May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National
Toggle Summary electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, N.J. , May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger , will be presenting at the H.C. Wainwright Global Investment Conference and LD Micro
Toggle Summary electroCore Announces Record First Quarter 2022 Financial Results
First quarter 2022 net sales of $1.9 million , approximately 58% over first quarter 2021 and 27% sequentially Company to host a conference call and webcast today, May 5, 2022 at, 4:30 PM EDT ROCKAWAY, N.J. , May 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.
Toggle Summary electroCore to Announce First Quarter 2022 Financial Results on May 5
ROCKAWAY, N.J. , April 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2022 , after the close of the market on Thursday, May 5, 2022 .